Why is Cochlear stock surging today?

Cochlear's shares jumped 7% to A$140.48 after the hearing implant company reported earnings that beat expectations. The company's underlying net profit for the year ended June 30 fell 22% to A$322.4 million, slightly below forecasts of A$303.9 million. However, cost reductions and improving margins helped offset weaker demand and currency issues.

For 2027, Cochlear expects low single-digit revenue growth and net profit between A$330 million and A$350 million. The stock rally is driven by optimism stemming from the company's revised expectations: Cochlear had drastically cut its FY26 profit guidance in April 2026 amid lower implant sales in developed markets, hospital capacity limits in Europe, slower-than-anticipated sales of its new Nucleus Nexa System, and a stronger Australian dollar.

Despite the broader market's flat performance, Cochlear outperformed, indicating investors are reassessing the company's outlook in a positive light.